Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| COAG | 3 | neutral | 2/10 | Benny Sorensen, the President and CEO of Hemab Therapeutics, filed an initial Form 3 disclosing beneficial ownership of | Apr 30, 2026 |
| INCR | PRESS-RELEASE | mixed | 6/10 | InterCure reported FY2025 revenue of NIS 270M (+13% YoY), a net loss of NIS 37M (improved from NIS 73M loss in 2024), an | Apr 30, 2026 |
| FBLG | PRESS-RELEASE | neutral | 5/10 | FibroBiologics reported Q1 2026 EPS of -$0.60, a 55.7% beat vs consensus of -$1.35, but net loss was flat YoY at $5.0M. | Apr 30, 2026 |
| MEOH | PRESS-RELEASE | bearish | 7/10 | Methanex reported Q1 2026 EPS of $0.30, a 28.6% miss versus the $0.42 consensus, with no revenue figure provided in the | Apr 30, 2026 |
| NRIX | CLUSTER | neutral | 2/10 | Two C-suite insiders at Nurix Therapeutics sold a combined $107K in open-market shares on April 30, 2026, following deri | Apr 30, 2026 |
| DBVTF | 8-K | neutral | 4/10 | DBV Technologies reported Q1 2026 financial results, showing a net loss of $47.6M, widening from $27.1M in Q1 2025, driv | Apr 30, 2026 |
| ESLAW | 10-K/A | neutral | 2/10 | Estrella Immunopharma filed Amendment No. 1 to its 2025 Form 10-K solely to add Part III information (directors, executi | Apr 30, 2026 |
| RNAZ | S-3 | bearish | 8/10 | TransCode Therapeutics filed an S-3 registration statement to register up to 15,955,543 shares of common stock for resal | Apr 30, 2026 |
| OCUL | DEFA14A | neutral | 3/10 | Ocular Therapeutix filed a DEFA14A (definitive additional proxy soliciting materials) providing notice of its 2026 Annua | Apr 30, 2026 |
| DYN | CLUSTER | neutral | 3/10 | Two Dyne Therapeutics directors sold a total of ~$1.15M in stock over a 7-day window, with Director Rhodes Jason P execu | Apr 30, 2026 |
| SNDX | DEFA14A | neutral | 3/10 | Syndax Pharmaceuticals filed a DEFA14A (additional definitive proxy soliciting materials) on April 30, 2026. The filing | Apr 30, 2026 |
| INCR | 20-F | bearish | 7/10 | InterCure's FY2025 20-F shows a 13% revenue increase to NIS 270M, driven by resumed Southern Facility production and fir | Apr 30, 2026 |
| AXSM | 8-K | bullish | 8/10 | Axsome Therapeutics announced FDA approval of AUVELITY for agitation associated with dementia due to Alzheimer's disease | Apr 30, 2026 |
| IMUX | S-3/A | bearish | 8/10 | Immunic filed Amendment No. 1 to its S-3 shelf registration to register the resale of up to 45,815,180 shares of common | Apr 30, 2026 |
| ALTO | DEFA14A | neutral | 2/10 | Alto Ingredients filed a DEFA14A (definitive additional proxy soliciting materials) on April 30, 2026. The filing is mar | Apr 30, 2026 |
| PHGE | 10-K/A | neutral | 3/10 | BiomX filed Amendment No. 1 to its 2025 10-K solely to add Part III items (directors, executive compensation, security o | Apr 30, 2026 |
| SCNX | 10-K/A | bearish | 7/10 | Scienture Holdings filed Amendment No. 1 to its 2025 10-K to correct immaterial errors in Item 7 (MD&A) and to include P | Apr 30, 2026 |
| AWHL | 8-K | neutral | 3/10 | Aspira Women's Health appointed John Strahley as CFO/CAO effective April 27, 2026, replacing Brian Hungerford who depart | Apr 30, 2026 |
| GTBP | S-1 | bearish | 7/10 | GT Biopharma filed an S-1 registration statement to register up to 9,723,057 shares of common stock for resale by sellin | Apr 30, 2026 |
| CLRB | 10-K/A | neutral | 2/10 | Cellectar Biosciences filed Amendment No. 1 to its 2025 Form 10-K solely to add Part III information (directors, executi | Apr 30, 2026 |
| VNRX | 10-K/A | neutral | 2/10 | VolitionRx filed Amendment No. 1 to its 2025 Form 10-K solely to include Part III information (directors, executive comp | Apr 30, 2026 |
| LGNYZ | 8-K | bearish | 6/10 | Ligand Pharmaceuticals terminated its TR-Beta Program license with Viking Therapeutics, alleging Viking materially breac | Apr 30, 2026 |
| SMMT | 8-K | neutral | 5/10 | Summit Therapeutics reported Q1 2026 financial results and operational progress. The company posted a GAAP net loss of $ | Apr 30, 2026 |
| IMA | DEFA14A | neutral | 3/10 | ImageneBio filed a DEFA14A (definitive additional proxy soliciting materials) on April 30, 2026. The filing is marked as | Apr 30, 2026 |
| PCSA | CLUSTER | bullish | 6/10 | Nine insiders at Processa Pharmaceuticals, including the CEO, CFO, and multiple directors, made open-market purchases to | Apr 30, 2026 |
| DBVT | PRESS-RELEASE | bullish | 5/10 | DBV Technologies reported Q1 2026 EPS of $(0.11), beating consensus of $(0.12) by 8.3%, and revenue of $0.9M, beating $8 | Apr 30, 2026 |
| EBS | PRESS-RELEASE | mixed | 6/10 | Emergent BioSolutions reported Q1 2026 adjusted net income per diluted share of $0.21, beating the consensus estimate of | Apr 30, 2026 |
| SYBX | 10-K/A | neutral | 2/10 | Synlogic filed Amendment No. 1 to its 2025 Form 10-K solely to include Part III items (director/officer info, executive | Apr 30, 2026 |
| PAHC | 8-K | neutral | 4/10 | Phibro Animal Health Corp. entered into Amendment No. 1 to its existing Credit Agreement, increasing its revolving credi | Apr 30, 2026 |
| CUE | PRESS-RELEASE | mixed | 6/10 | Cue Biopharma licensed global rights (ex-China) to Ascendant-221, a Phase 2 anti-IgE antibody for allergic diseases, fro | Apr 30, 2026 |